Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
  • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/121—Ketones acyclic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system

Definitions

• TITLE USE OF A VANILLOID AS ANTI-SNORING
• the present invention relates to novel compositions useful against snoring and sleep apnea. It relates in particular to the use of a vanilloid to prevent, reduce or suppress snoring.
• snoring is not considered a health problem. In general it does not annoy the person who snores, but can considerably annoy those around him. Snoring is more common in men (20 to 32%) than women (8%) (Jennum P et al., J Sleep Res., 1992, 1, p.240-244 and Teculescu et al., Respiration 2001 , 68 (4 ⁇ p.365- 370), and more in obese people than thin people.
• the typical noise of snoring occurs when the soft tissues of the upper respiratory tract vibrate with the passage of air, which can be caused by one or more of four different situations:
• a polyp is a longiform growth which occurs on a mucous membrane
• Certain medications such as antihistamines or hypnotics can cause your throat muscles to relax too much and make snoring easier.
• Sleep apnea consists of more or less long, more or less followed respiratory stops, after which breathing resumes with noise. It is a problem that causes fatigue, mood swings, depression and even heart problems due to poor sleep and the dangerous drop in blood pressure.
• snoring problems are mainly treated by surgery which aims to modify the topology of the upper airways (veloplasty, somnoplasty, somnoplasty by injection etc.).
• veloplasty, somnoplasty, somnoplasty by injection etc. There are also various accessories supposed to come to the aid of snorers: pillows to better position the head, nasal orthosis to keep the air passage open etc.
• Some products to treat snoring problems are also available, in particular essential oils but without much success (WO 00/25588).
• a vanilloid can be used to prevent, suppress or decrease snoring and to treat sleep apnea.
• Gingerol another member of the vanilloid family, is also known to be a constituent of ginger belonging to the Zingiber officinalis family.
• Anti-snoring compositions comprising as main components an extract of Zingiber officinale and Dioscorea (Dioscorea villosa or Dioscoreaceae among others) have also been described (US 5,565,201, US 5,603,935, US 5,804,211).
• Zingiber officmale extract has never been described as having an action against snoring on its own. On the contrary, the presence of the second component seems essential (synergy of actions).
• the vanilloids alone can be active anti-snoring.
• the present invention therefore relates to the use of a vanilloid to reduce, suppress or prevent snoring.
• vanilloid means any chemical molecule corresponding to any one of the following general formulas:
• X represents a linear, saturated, mono-unsaturated or polyunsaturated, substituted or unsubstituted C ⁇ -C 4 alkyl group
• Y is chosen from the groups -N (H) C (O) -, -C (O) N-, and -C (O) -;
• RI represents a linear, branched or cyclic chain, saturated, monounsaturated or polyunsaturated, substituted or unsubstituted C 2 -C 24 alkyl group.
• the vanilloid is chosen from the group consisting of capsaicin, piperine, gingerols and shogaols.
• it is one or more shogaols.
• the present invention relates to the use of a vanilloid for the manufacture of a medicament for treating sleep apnea.
• capsaicin corresponds to the following general formula:
• the capsicum fruit powder is obtained by percolation of the capsicum fruit powder and then purification of the capsicin thus obtained. It is also commercially available.
• the piperine is obtained by extraction of the pericarp from the black pepper. It is also commercially available.
• the shogaol (s) correspond (s) to the general formula (III):
• n is equal to 1, 2, 4, 6 or 8 and which are respectively named [3] - shogaol, [4] -shogaol, [6] -shogaol, [8] -shogaol and [10] -shogaol. Even more advantageously, it is [3] -shogaol.
• the shogaol (s) are in the form of a crude extract of a plant of the family Zingiberaceae, advantageously by a process which comprises the following step: a) preparation of crude extract from rhizomes, fresh or dried, of said plant, by maceration of a ground material of these rhizomes at a temperature between 10 and 35 ° C, followed by one or more reflux extractions of this ground material, or by subjecting a ground material of said rhizomes to percolation at a temperature between 10 and 35 ° C, each of these operations (maceration, reflux extractions and percolation) being carried out using an organic solvent or a mixture of appropriate organic solvents .
• the maceration of the ground rhizomes, prior to its extraction, has the main effect of improving the contacting of the plant tissues and the solvent during the extraction. Its duration can be between a dozen hours and a week depending on the state of freshness of the rhizomes used.
• organic solvents are used which are miscible with water and have a relatively low boiling point so that they can be easily removed later by simple evaporation. , such as ethanol, methanol, acetone or their mixtures with water.
• shogaols are soluble in many organic solvents, it is also other organic solvents such as ethyl acetate, ethyl ether, chloroform or methylene chloride can be used.
• the shogaol (s) are in the form of a purified extract of a plant of the family Zingiberaceae, advantageously obtained by a process which comprises, in addition to step a) described below above, the following additional steps: b) purification of the crude extract obtained in step a) by subjecting said extract, after elimination of the solvent or solvents which it contains and its recovery in water, to one or more several extractions against the current using an organic solvent or a mixture of organic solvents immiscible with water and, if desired, c) cliromatographic separation of the shogaols.
• the water-immiscible organic solvent (s) useful for carrying out the counter-current extractions of the crude extract with a view to its purification are, in particular, chosen from ethyl acetate, ethyl ether, chloroform , methylene chloride and mixtures thereof.
• the plant of the family Zingiberaceae is chosen from the species Alpinia galanga, Alpinia officinarum, Zingiber officinalis, Zingiber cassumunar and Zingiber zerumbet, even more advantageously, it is / Alpinia galanga.
• [3] -shogaol, [6] -shogaol and [8] -shogaol can be extracted from plants of the genus Alpinia such as Alpinia galanga or Alpinia officinarum, while [4] -shogaol and [10] -shogaol can be extracted from plants of the genus Zingiber such as Zingiber officinalis, Zingiber cassumunar or Zingiber zerumbet, in particular using the method as described above.
• the crude extract from Alpinia galanga contains an amount of [3] - shogaol comprised by weight between approximately 1 to 5% of the dry weight of said extract.
• this extract is obtained from rhizomes, fresh or dry, of said plant.
• the purified extract & Alpinia galanga contains an amount of [3] -shogaol at least equal by weight to 75% of the dry weight of said extract.
• the present invention also relates to the use of a vanilloid for the preparation of an anti-snoring composition.
• the anti-snoring composition is formulated for oral administration, for example, in the form of powders, solutions or oral suspensions, syrups, tablets or capsules.
• composition is formulated in the form of a nasal or oral spray.
• Physiologically acceptable excipients can be used in this type of composition. These excipients are conventional and well known to those skilled in the art.
• the vanilloid is used at a daily dose corresponding to 20 mg of vanilloid taken in the form of plant extract or pure vanilloid.
• it is in this case shogaol.
• Example 1 Preparation of a crude extract of rhizomes of Alpinia galanga
• a kilo of fresh rhizomes tf Alpinia galanga is coarsely ground, taking care not to cause excessive heating of the ground parts.
• the water content of the ground product thus obtained is determined and it is macerated in 7 liters of ethanol, the title of which is chosen so that, taking into account the water content of the ground material, the maceration solvent is 50% ethanol.
• the ground material is extracted at reflux with the maceration solvent for 30 minutes. This solvent is removed and replaced with an equal weight of 50% ethanol, and the ground material is again extracted at reflux for 30 minutes. The operation is repeated once.
• the 3 extracts obtained are combined (thus constituting a volume of about 19 liters), filtered on paper, then evaporated to dryness under reduced pressure.
• a residue is obtained which weighs approximately 50 g, ie an approximate yield of 30% relative to the dry weight of the rhizomes.
• This extract contains the different shogaols present in the rhizomes of Alpinia galanga ([3] -shogaol, [6] -shogaol and [8] -shogaol) and its [3] -shogaol content is generally between 1 and 5% (w / w) depending on the rhizomes used.
• [3] -shogaol can be obtained from Alpinia galanga rhizomes by preparing a crude extract of these rhizomes in accordance with Example 1, then purifying this extract in accordance with Example 2 and then subjecting the extract thus purified by successive elutions on columns of silica gel, for example in the following manner. 10 g of a purified extract, prepared in accordance with Example 2, are added with 100 g of silica gel G60 and 500 ml of chloroform with constant stirring. As soon as this mixture is homogeneous, it is evaporated to dryness under reduced pressure so as to obtain a powder.
• This powder is deposited at the top of a column 10 cm in diameter and 50 cm in height, also containing G60 silica gel in petroleum ether.
• the chloroform phase is evaporated to dryness under reduced pressure, leaving room for a residue of approximately 2.3 g.
• This residue is then subjected to preparative chromatography on a column 5 cm in diameter and 20 cm in height, filled with Cl 8 silica gel, and using a water / acetonitrile mixture (70/30) as elution gradient. .
• the fraction containing [3] -shogaol is eluted in a time between 5 and 7 minutes for a flow rate of 30 ml / min.
• [3] -shogaol can be identified by high pressure liquid chromatography (HPLC) coupled with mass spectrometry.
• HPLC high pressure liquid chromatography
• This powder was then distributed in No. 0 capsules so as to obtain a unit dosage of 250 mg of crude extract.
• capsules can be made from [3] -shogaol to obtain a unit dosage of 25 mg of [3] -shogaol.
• Example 5 activity of shogaol on snoring:
• Shogaol significantly reduces snoring in users.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicines Containing Plant Substances (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=27799229

Family Applications (1)

Country Status (5)

Families Citing this family (4)

Family Cites Families (6)

• 2002
  • 2002-03-25 FR FR0203681A patent/FR2837390A1/fr active Pending
• 2003
  • 2003-03-25 WO PCT/FR2003/000936 patent/WO2003080036A2/fr not_active Application Discontinuation
  • 2003-03-25 EP EP03738193A patent/EP1487425A2/de not_active Withdrawn
  • 2003-03-25 AU AU2003244710A patent/AU2003244710A1/en not_active Abandoned
  • 2003-03-25 US US10/509,048 patent/US20050118287A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events